{"description":"Stopping Rules for excess toxicity:\n\n* Any non-hematologic grade 4 toxicity except for fevers alone\n* Grade III/IV GvHD or GvHD requiring more than 7 days of therapy\n* Hematologic toxicity: prolonged neutropenia defined as an absolute neutrophil count of less than 500 on day +35. Prolonged anemia or thrombocytopenia will not constitute toxicity.","eventGroups":[{"description":"Patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukemia treated with 1 dose donor natural killer cells infusion, 4 doses rituximab, 6 doses aldesleukin and 5 doses fludarabine and 1 dose cyclosphosphamide.","id":"EG000","otherNumAffected":0,"otherNumAtRisk":6,"seriousNumAffected":5,"seriousNumAtRisk":6,"title":"Patients Treated With Natural Killer Cells"}],"frequencyThreshold":"5","seriousEvents":[{"assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"Ventricular arrhythmia - Bigeminy","organSystem":"Cardiac disorders","sourceVocabulary":"CTCAE (3.0)","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":6,"numEvents":1}],"term":"Cardiac Arrhythmia"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"General disorders","sourceVocabulary":"CTCAE (3.0)","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":6,"numEvents":3}],"term":"Death - Disease Progression NOS"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Infections and infestations","sourceVocabulary":"CTCAE (3.0)","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":6,"numEvents":2}],"term":"Infection"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"ANC \\<500 at day +35","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"CTCAE (3.0)","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":6,"numEvents":1}],"term":"Neutrophils/granulocytes (ANC/AGC)"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"CTCAE (3.0)","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":6,"numEvents":1}],"term":"Pulmonary - obstruction/stenosis of airway"}],"timeFrame":"Serious adverse events were collected after start of chemotherapy treatment (Day -1) through date of death (all within 6 months)."}